XML 13 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements Of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended 272 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Revenue   $ 35   $ 35 $ 3,166
Operating expenses:          
Research and development 27,281 25,453 80,731 76,247 1,548,304
General and administrative 17,481 10,069 42,053 37,262 467,757
In-process research and development costs         19,726
Goodwill impairment         151,428
Total operating expenses 44,762 35,522 122,784 113,509 2,187,215
Loss from operations (44,762) (35,487) (122,784) (113,474) (2,184,049)
Other income (expense) 10 (2,651) 48 12,078 (2,219)
Interest expense on note payable to related party (1,745) (2,245) (5,123) (8,321) (43,948)
Interest expense on senior convertible notes and facility financing obligation (4,323) (2,859) (10,052) (8,278) (49,985)
Interest income 2   4 2 37,000
Loss before benefit for income taxes (50,818) (43,242) (137,907) (117,993) (2,243,201)
Income tax benefit   408   408 382
Net loss (50,818) (42,834) (137,907) (117,585) (2,242,819)
Deemed dividend related to beneficial conversion feature of convertible preferred stock         (22,260)
Accretion on redeemable preferred stock         (952)
Net loss applicable to common stockholders $ (50,818) $ (42,834) $ (137,907) $ (117,585) $ (2,266,031)
Net loss per share applicable to common stockholders - basic and diluted $ (0.17) $ (0.22) $ (0.48) $ (0.71)  
Shares used to compute basic and diluted net loss per share applicable to common stockholders 296,386 190,534 286,889 164,611